ACNE

  • Phase 3, topical treatment
    • Qualifications: ≥20 red pimples on face & ≥20 on torso (excludes white heads, blackheads and/or scars)
      • Male or female, ≥9 years
    • Includes: Physical Exams, Vital Signs & blood work
    • Duration: 14 weeks
  • Phase 4, topical treatment
    • Qualifications: ≥20 red pimples on face (excludes white heads, blackheads and/or scars); grade of ≥2 on IGA scale
      • Male or female, ≥9 years to ≤11 years
    • Includes: Physical Exams, Photography & blood work
    • Duration: 12 weeks



PSORIASIS

  • Phase 3, injectable treatment
    • Qualifications: Diagnosed with psoriasis for at least 6 months
      • Must have BSA of ≥10%
      • Must be a systemic therapy candidate
      • Male or female, ≥18 years to ≤80 years
    • Includes: Physical Exams, ECG’s, Vital Signs, chest X-ray & blood work
    • Duration: 33 weeks/~8 months
  • Phase 4, injectable treatment
    • Qualifications: Diagnosed with psoriasis for at least 6 months
      • Must have moderate-to-severe psoriasis
        • BSA of ≥10%
        • PASI score of ≥12 and IGA score of ≥3 (based on 0-4 scale)
      • Must be a candidate for systemic therapy
      • Male or female, ≥18 years
      • Must have open availability to comply with weekly visits
    • Includes: Physical Exams, Vital Signs & blood work; No ECG’s
    • Duration: 57 weeks

       

ALOPECIA

  • Phase 2a, topical treatment
    • Qualifications: Moderate to severe alopecia areata (≥50% hair loss of scalp without evidence of hair regrowth within 6 months)
      • current episode of hair loss ≤7
      • Male or female, ≥18 years to ≤75 years
    • Includes: Physical Exams, ECG’s, Vital Signs, chest X-ray, biopsies & blood work
    • Duration: 8 months


 
ATOPIC DERMATITIS


  • Phase 2, injectable treatment
    • Qualifications: BSA of ≥10%, IGA score of ≥3, and EASI score of ≥16
      • Male or female, ≥12 years to ≤70 years
      • Skin biopsy
    • Includes: Physical Exams, ECG’s, Vital Signs & blood work
    • Duration: 20 weeks

Clinical trials are research studies that explore whether a medical strategy, treatment, or device is safe and effective for humans.


These trials are closely regulated by the Food and Drug Administration as well as central governing entities called Institutional Review Boards. These studies also may show which medical approaches work best for certain illnesses or individuals. 

PREVIOUS CLINICAL TRIALS

8/2010 - 7/2015   Principal Investigator, University of California, Irvine, Dept of Dermatology

  • A Prospective, Observational Study to Estimate the Proportion of Subjects With Plaque Psoriasis Who Achieve Complete Clearance on Biologics
  • A Phase 2b, Multi-site, Randomized, Double-blind, Vehicle-controlled, Parallel-group Study Of The Efficacy, Safety, Local Tolerability And Pharmacokinetics Of 2 Dose Strengths And 2 Regimens Of Tofacitinib Ointment In Subjects With Chronic Plaque Psoriasis
  • A Phase 3b, Multicenter, Randomized, Placebo-Controlled, Double Blind, Double-Dummy, Study of the Efficacy and Safety of Apremilast (CC-10004), Etanercept, and Placebo, in Subjects With Moderate to Severe Plaque Psoriasis
  • An Open-label Study to Evaluate the Effect of Brodalumab on the Pharmacokinetics of Midazolam and Assess Single-Dose Brodalumab Pharmacokinetics in Subjects With Moderate to Severe Plaque Psoriasis
  • A Phase 2a, Open-Label Study to Evaluate the Safety and Tolerability of KD025 Treatment in Subjects With Moderately Severe Psoriasis Vulgaris Who Have Failed First-Line Therapy
  • The Safety and Efficacy Study to Compare Dapsone Dermal Gel with Vehicle Control in Patients with Acne Vulgaris
  • A Phase 3b, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis
  • A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
  • A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
  • ​Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
  • A Multiple-Dose (0.3%, 1%, and 3% [w/w]), Randomized, Blinded, Vehicle- and Active Comparator-Controlled, Sequential Dose Cohorts, Multi-Center Trial to Assess the Safety, Pharmacokinetics, and Proof-of-Concept Efficacy of Topical OPA 15406 Ointment, Applied Twice Daily for 28 Days, in Adult Subjects With Atopic Dermatitis
  • A Randomised, Controlled, Multidose, Multicentre, Adaptive Phase II/III Study in Infants With Proliferating Infantile Hemangiomas (IHs) Requiring Systemic Therapy to Compare 4 Regimens of Propranolol (1 or 3 mg/kg/Day for 3 or 6 Months) to Placebo (Double Blind)


8/2007 - 7/2008   Principal Investigator, Psoriasis Foundation Gene Bank

7/2006 – 6/2007  Sub-Investigator, Mount Sinai School of Medicine, Dept of Dermatology

  • Plaque psoriasis study - Oral
  • Phase 3 Plaque psoriasis study - Sub-Cutaneous
  • Phase 3 Plaque psoriasis study - Sub-Cutaneous
  • Plaque psoriasis observational study

As the former Director of Clinical Research at University of California, Irvine and the principal investigator of multiple Dermatology clinical trials, Dr. Jennifer Soung is a leader in clinical research and advanced treatments for chronic skin conditions such as psoriasis, eczema and skin cancer.

What are the advantages of participating in a clinical trial?
In addition to offering new treatments for skin conditions, clinical trial patients are generally more closely monitored than patients outside of clinical trials. This includes in-office examinations by a board certified dermatologist, more time with staff, and more assessments such as blood draws, x-rays, and electrocardiograms. Participation in a trial is at no cost and typically compensation for time and travel is provided. By far the most important reason to participate in a clinical trial is to treat a medical condition. Our staff will discuss each trial at length with you if you think you might benefit.

Do I have to stay in a clinical trial?
Participation in a trial is always voluntary. Dr. Jennifer Soung and her staff will discuss all treatment options with you to help you make a decision. Once you are in the trial, you can stop participation at any time for any reason.

What are the phases of clinical trials?
Clinical trials go through 3 phases before a drug is submitted to the FDA for approval. Phase 1 is a very limited trial during which the safety of the drug is assessed. Phase 2 trials are to establish both the effectiveness and safety of a medication. Phase 3 trials are to ensure that it is effective and safe in a broad range of patients for a long term.

How do I sign up for a trial?
As trials are available, they will be posted on this website along with some general criteria of who might be eligible for participation. If you are interested, please contact the office at (714) 474-2173. If you qualify for a study, you will be contacted and scheduled for a pre-screening visit. 

FAQ

Jennifer Soung, MD

Dermatologist

ACTIVE CLINICAL TRIALS

​​WHAT IS A CLINICAL TRIAL?